

[illegible]

†transfusion; 2 mm/pla; hybrid He.
Hem. sapiens.
Key: 100014/100015


W09325071 A.
23 DEC 1993

[illegible][illegible][illegible]

The sequences given in Table 1 are known to be highly conserved among all eukaryotic species. The human alpha chain sequence, designated alpha₁, is identical to that of the mouse alpha₁ chain.

specification of the gene could be used for the same purpose as the above system of gene selection. In this case, the gene could be used to produce the transgenic pigs of the invention. These pigs could contain the beta-gal gene promoter, serving as a marker gene, and a human alpha-1 fetoprotein gene. The containing these genes could express human α -fetoprotein (hAFP) in their serum. The pigs could be suffering no noticeable side effects as a result of the presence of hAFP production. They can be used as an efficient and convenient source of human hAFP that can be used for the same purpose as the above system.

[illegible][illegible]



UNCLASSIFIED//FOR OFFICIAL USE ONLY
TO: DIRECTOR, FBI (100-443100)
FROM: SAC, NEW YORK (100-100000)
SUBJECT: [REDACTED]
RE: [REDACTED]
DATE: 11/15/99
TIME: 07:40:34
BY: [REDACTED]

100-443100-100000

100-443100-100000
100-443100-100000
100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000
100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

UNCLASSIFIED//FOR OFFICIAL USE ONLY
TO: DIRECTOR, FBI (100-443100)
FROM: SAC, NEW YORK (100-100000)
SUBJECT: [REDACTED]
RE: [REDACTED]
DATE: 11/15/99
TIME: 07:40:34
BY: [REDACTED]

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000

100-443100-100000



10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM
10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM
10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM

10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM
10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM

10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM
10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM 10/11/1999 10:11:11 AM



[illegible]

1. $\frac{1}{2}$
 2. $\frac{1}{2}$
 3. $\frac{1}{2}$
 4. $\frac{1}{2}$
 5. $\frac{1}{2}$
 6. $\frac{1}{2}$
 7. $\frac{1}{2}$
 8. $\frac{1}{2}$
 9. $\frac{1}{2}$
 10. $\frac{1}{2}$
 11. $\frac{1}{2}$
 12. $\frac{1}{2}$
 13. $\frac{1}{2}$
 14. $\frac{1}{2}$
 15. $\frac{1}{2}$
 16. $\frac{1}{2}$
 17. $\frac{1}{2}$
 18. $\frac{1}{2}$
 19. $\frac{1}{2}$
 20. $\frac{1}{2}$
 21. $\frac{1}{2}$
 22. $\frac{1}{2}$
 23. $\frac{1}{2}$
 24. $\frac{1}{2}$
 25. $\frac{1}{2}$
 26. $\frac{1}{2}$
 27. $\frac{1}{2}$
 28. $\frac{1}{2}$
 29. $\frac{1}{2}$
 30. $\frac{1}{2}$
 31. $\frac{1}{2}$
 32. $\frac{1}{2}$
 33. $\frac{1}{2}$
 34. $\frac{1}{2}$
 35. $\frac{1}{2}$
 36. $\frac{1}{2}$
 37. $\frac{1}{2}$
 38. $\frac{1}{2}$
 39. $\frac{1}{2}$
 40. $\frac{1}{2}$
 41. $\frac{1}{2}$
 42. $\frac{1}{2}$
 43. $\frac{1}{2}$
 44. $\frac{1}{2}$
 45. $\frac{1}{2}$
 46. $\frac{1}{2}$
 47. $\frac{1}{2}$
 48. $\frac{1}{2}$
 49. $\frac{1}{2}$
 50. $\frac{1}{2}$
 51. $\frac{1}{2}$
 52. $\frac{1}{2}$
 53. $\frac{1}{2}$
 54. $\frac{1}{2}$
 55. $\frac{1}{2}$
 56. $\frac{1}{2}$
 57. $\frac{1}{2}$
 58. $\frac{1}{2}$
 59. $\frac{1}{2}$
 60. $\frac{1}{2}$
 61. $\frac{1}{2}$
 62. $\frac{1}{2}$
 63. $\frac{1}{2}$
 64. $\frac{1}{2}$
 65. $\frac{1}{2}$
 66. $\frac{1}{2}$
 67. $\frac{1}{2}$
 68. $\frac{1}{2}$
 69. $\frac{1}{2}$
 70. $\frac{1}{2}$
 71. $\frac{1}{2}$
 72. $\frac{1}{2}$
 73. $\frac{1}{2}$
 74. $\frac{1}{2}$
 75. $\frac{1}{2}$
 76. $\frac{1}{2}$
 77. $\frac{1}{2}$
 78. $\frac{1}{2}$
 79. $\frac{1}{2}$
 80. $\frac{1}{2}$
 81. $\frac{1}{2}$
 82. $\frac{1}{2}$
 83. $\frac{1}{2}$
 84. $\frac{1}{2}$
 85. $\frac{1}{2}$
 86. $\frac{1}{2}$
 87. $\frac{1}{2}$
 88. $\frac{1}{2}$
 89. $\frac{1}{2}$
 90. $\frac{1}{2}$
 91. $\frac{1}{2}$
 92. $\frac{1}{2}$
 93. $\frac{1}{2}$
 94. $\frac{1}{2}$
 95. $\frac{1}{2}$
 96. $\frac{1}{2}$
 97. $\frac{1}{2}$
 98. $\frac{1}{2}$
 99. $\frac{1}{2}$
 100. $\frac{1}{2}$

[illegible][illegible]

Mon Nov 15 07:40:38 1999

US-08-832-443-10.rai

Page 8

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes that proper record-keeping is essential for transparency and accountability, particularly in financial matters. The text outlines various methods for organizing and storing data, including digital databases and physical filing systems. It also mentions the need for regular audits and reviews to ensure the integrity of the information.

2. The second section focuses on the role of communication in achieving organizational goals. It highlights the importance of clear and concise communication, both internally and externally. The text provides examples of effective communication strategies, such as regular team meetings, open-door policies, and the use of collaborative tools. It also discusses the challenges of communication in a remote or distributed work environment and offers solutions to overcome these challenges.

3. The third part of the document addresses the issue of time management and productivity. It stresses the importance of prioritizing tasks and setting realistic deadlines. The text provides practical tips for managing time, such as creating a daily schedule, delegating responsibilities, and avoiding multitasking. It also discusses the benefits of taking regular breaks and maintaining a healthy work-life balance to prevent burnout and maintain high productivity levels.

4. The final section discusses the importance of continuous learning and professional development. It encourages individuals to stay up-to-date with the latest industry trends and technologies. The text provides suggestions for finding learning opportunities, such as attending conferences, taking courses, and seeking mentorship. It also emphasizes the importance of applying new knowledge and skills to the workplace to drive innovation and growth.

11 10/15/99 07:40:41 N/A
12 10/15/99 07:40:41 N/A
13 10/15/99 07:40:41 N/A
14 10/15/99 07:40:41 N/A
15 10/15/99 07:40:41 N/A
16 10/15/99 07:40:41 N/A
17 10/15/99 07:40:41 N/A
18 10/15/99 07:40:41 N/A
19 10/15/99 07:40:41 N/A
20 10/15/99 07:40:41 N/A

21 10/15/99 07:40:41 N/A
22 10/15/99 07:40:41 N/A
23 10/15/99 07:40:41 N/A
24 10/15/99 07:40:41 N/A
25 10/15/99 07:40:41 N/A
26 10/15/99 07:40:41 N/A
27 10/15/99 07:40:41 N/A
28 10/15/99 07:40:41 N/A
29 10/15/99 07:40:41 N/A
30 10/15/99 07:40:41 N/A

31 10/15/99 07:40:41 N/A
32 10/15/99 07:40:41 N/A
33 10/15/99 07:40:41 N/A
34 10/15/99 07:40:41 N/A
35 10/15/99 07:40:41 N/A
36 10/15/99 07:40:41 N/A
37 10/15/99 07:40:41 N/A
38 10/15/99 07:40:41 N/A
39 10/15/99 07:40:41 N/A
40 10/15/99 07:40:41 N/A

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and the role of the accounting system in providing reliable financial information. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods used to collect and analyze financial data, including the use of statistical techniques and the application of mathematical models. It highlights the importance of using appropriate methods to ensure the accuracy and reliability of the results.

3. The third part of the document discusses the challenges faced by organizations in managing their financial resources and the importance of developing effective financial management strategies. It emphasizes the need for a clear understanding of the organization's financial position and the ability to make informed decisions based on that information.

4. The fourth part of the document discusses the importance of maintaining accurate records of all transactions and the role of the accounting system in providing reliable financial information. It emphasizes the need for transparency and accountability in financial reporting.

5. The fifth part of the document outlines the various methods used to collect and analyze financial data, including the use of statistical techniques and the application of mathematical models. It highlights the importance of using appropriate methods to ensure the accuracy and reliability of the results.

6. The sixth part of the document discusses the challenges faced by organizations in managing their financial resources and the importance of developing effective financial management strategies. It emphasizes the need for a clear understanding of the organization's financial position and the ability to make informed decisions based on that information.

7. The seventh part of the document discusses the importance of maintaining accurate records of all transactions and the role of the accounting system in providing reliable financial information. It emphasizes the need for transparency and accountability in financial reporting.

8. The eighth part of the document outlines the various methods used to collect and analyze financial data, including the use of statistical techniques and the application of mathematical models. It highlights the importance of using appropriate methods to ensure the accuracy and reliability of the results.

9. The ninth part of the document discusses the challenges faced by organizations in managing their financial resources and the importance of developing effective financial management strategies. It emphasizes the need for a clear understanding of the organization's financial position and the ability to make informed decisions based on that information.

10. The tenth part of the document discusses the importance of maintaining accurate records of all transactions and the role of the accounting system in providing reliable financial information. It emphasizes the need for transparency and accountability in financial reporting.


```

#1: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#2: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#3: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#4: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#5: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#6: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#7: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#8: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#9: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#10: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#11: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#12: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#13: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#14: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#15: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#16: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#17: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#18: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#19: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#20: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00

```

Search completed: Fri Nov 12 07:41:07 1999
J04 time: 13 secs.

```

#1: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#2: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#3: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#4: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#5: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#6: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#7: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#8: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#9: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#10: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#11: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#12: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#13: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#14: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#15: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#16: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#17: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#18: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#19: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00
#20: 11/15/99 07:41:07 (11/15/99) 01:00:00 01:00:00

```

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

Figure 1. The effect of the number of trials on the number of correct responses. The number of correct responses was significantly higher for the 10 trials condition than for the 5 trials condition. Error bars represent the standard error of the mean.

[illegible]

1. *Pharmaceutical industry* – The pharmaceutical industry is a major player in the healthcare sector, responsible for the development, production, and distribution of drugs. It is a highly regulated industry with significant research and development costs. The industry is often criticized for high prices and lack of transparency.

2. *Healthcare providers* – Healthcare providers, including hospitals, clinics, and individual practitioners, are the primary users of pharmaceuticals. They are responsible for diagnosing patients, prescribing medications, and monitoring their effectiveness. Healthcare providers often face pressure from payers (insurance companies and governments) to reduce costs, which can impact their ability to provide the best care.

3. *Payors* – Payors, including insurance companies and governments, are responsible for paying for healthcare services. They often negotiate with pharmaceutical companies to secure lower prices for their members. Payors also play a role in determining which medications are covered by insurance plans.

4. *Patients* – Patients are the ultimate recipients of healthcare services. They are responsible for paying for their care (either out-of-pocket or through insurance) and for following their healthcare provider's instructions. Patients often have limited choice in the medications they receive, as they are typically prescribed what the healthcare provider believes is the best option.

5. *Regulators* – Regulators, including the FDA and other government agencies, are responsible for ensuring the safety and effectiveness of pharmaceuticals. They oversee the drug approval process, monitor drug safety, and enforce regulations related to drug marketing and distribution.

6. *Pharmaceutical associations* – Pharmaceutical associations, such as the Pharmaceutical Research and Manufacturers of America (PhRMA), represent the interests of the pharmaceutical industry. They lobby on behalf of the industry and provide information to policymakers.

7. *Academic institutions* – Academic institutions, including universities and research centers, are involved in the discovery and development of new drugs. They often receive funding from the pharmaceutical industry and government agencies.

8. *Healthcare reform* – Healthcare reform efforts, such as the Affordable Care Act (ACA), aim to improve the healthcare system and reduce costs. These efforts often involve changes to the way pharmaceuticals are paid for and distributed.

9. *Global health* – Global health organizations, such as the World Health Organization (WHO), are concerned with the health of people around the world. They often focus on improving access to essential medicines and addressing public health challenges.

10. *Pharmaceutical innovation* – Pharmaceutical innovation is the process of developing new drugs and therapies. It is a complex and costly process that involves many steps, from target identification to clinical trials and approval.

11. *Pharmaceutical marketing* – Pharmaceutical marketing is the process of promoting drugs to healthcare providers and patients. It often involves direct-to-consumer advertising and sales representative visits.

12. *Pharmaceutical distribution* – Pharmaceutical distribution is the process of getting drugs from the manufacturer to the point of care. It often involves a network of wholesalers and distributors.

13. *Pharmaceutical pricing* – Pharmaceutical pricing is the process of determining the price of a drug. It is often a complex process that involves many factors, including the cost of development and production, the value of the drug, and the competitive landscape.

14. *Pharmaceutical transparency* – Pharmaceutical transparency is the process of making information about drugs and the industry more accessible to the public. This can include information about drug prices, clinical trial results, and industry funding.

15. *Pharmaceutical reform* – Pharmaceutical reform is the process of making changes to the pharmaceutical system to improve its performance. This can include changes to drug pricing, regulation, and distribution.

[illegible]

1. The following information was obtained from the New York Times on 11/15/99:

2. The following information was obtained from the New York Times on 11/15/99:

3. The following information was obtained from the New York Times on 11/15/99:

4. The following information was obtained from the New York Times on 11/15/99:



[illegible][illegible]

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

1. The first step in the process of identifying a problem is to determine the nature of the problem. This involves gathering information about the problem and its context. The next step is to identify the causes of the problem. This involves analyzing the information gathered in the first step and identifying the factors that are contributing to the problem. The third step is to develop a plan to address the problem. This involves identifying the goals of the plan and the steps that need to be taken to achieve those goals. The fourth step is to implement the plan. This involves putting the plan into action and monitoring its progress. The fifth step is to evaluate the results of the plan. This involves comparing the actual results with the goals of the plan and identifying any areas for improvement.

[illegible]
$$\begin{array}{c} \bullet f_1 \\ \bullet f_2 \\ \bullet f_3 \\ \bullet f_4 \\ \bullet f_5 \\ \bullet f_6 \\ \bullet f_7 \\ \bullet f_8 \\ \bullet f_9 \\ \bullet f_{10} \\ \bullet f_{11} \\ \bullet f_{12} \\ \bullet f_{13} \\ \bullet f_{14} \\ \bullet f_{15} \\ \bullet f_{16} \\ \bullet f_{17} \\ \bullet f_{18} \\ \bullet f_{19} \\ \bullet f_{20} \\ \bullet f_{21} \\ \bullet f_{22} \\ \bullet f_{23} \\ \bullet f_{24} \\ \bullet f_{25} \\ \bullet f_{26} \\ \bullet f_{27} \\ \bullet f_{28} \\ \bullet f_{29} \\ \bullet f_{30} \\ \bullet f_{31} \\ \bullet f_{32} \\ \bullet f_{33} \\ \bullet f_{34} \\ \bullet f_{35} \\ \bullet f_{36} \\ \bullet f_{37} \\ \bullet f_{38} \\ \bullet f_{39} \\ \bullet f_{40} \\ \bullet f_{41} \\ \bullet f_{42} \\ \bullet f_{43} \\ \bullet f_{44} \\ \bullet f_{45} \\ \bullet f_{46} \\ \bullet f_{47} \\ \bullet f_{48} \\ \bullet f_{49} \\ \bullet f_{50} \\ \bullet f_{51} \\ \bullet f_{52} \\ \bullet f_{53} \\ \bullet f_{54} \\ \bullet f_{55} \\ \bullet f_{56} \\ \bullet f_{57} \\ \bullet f_{58} \\ \bullet f_{59} \\ \bullet f_{60} \\ \bullet f_{61} \\ \bullet f_{62} \\ \bullet f_{63} \\ \bullet f_{64} \\ \bullet f_{65} \\ \bullet f_{66} \\ \bullet f_{67} \\ \bullet f_{68} \\ \bullet f_{69} \\ \bullet f_{70} \\ \bullet f_{71} \\ \bullet f_{72} \\ \bullet f_{73} \\ \bullet f_{74} \\ \bullet f_{75} \\ \bullet f_{76} \\ \bullet f_{77} \\ \bullet f_{78} \\ \bullet f_{79} \\ \bullet f_{80} \\ \bullet f_{81} \\ \bullet f_{82} \\ \bullet f_{83} \\ \bullet f_{84} \\ \bullet f_{85} \\ \bullet f_{86} \\ \bullet f_{87} \\ \bullet f_{88} \\ \bullet f_{89} \\ \bullet f_{90} \\ \bullet f_{91} \\ \bullet f_{92} \\ \bullet f_{93} \\ \bullet f_{94} \\ \bullet f_{95} \\ \bullet f_{96} \\ \bullet f_{97} \\ \bullet f_{98} \\ \bullet f_{99} \\ \bullet f_{100} \end{array}$$

[illegible]

July 1964

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes that proper record-keeping is essential for transparency and accountability, particularly in financial matters. The text outlines various methods for organizing and storing data, including digital databases and physical filing systems. It also mentions the need for regular audits and reviews to ensure the integrity of the information.

2. The second section focuses on the role of communication in achieving organizational goals. It highlights the importance of clear and concise communication, both internally and externally. The text provides examples of effective communication strategies, such as regular team meetings, open-door policies, and the use of collaborative tools. It also discusses the challenges of communication in a remote or distributed work environment and offers suggestions for overcoming these challenges.

3. The third part of the document addresses the issue of time management and productivity. It stresses the importance of prioritizing tasks and setting realistic deadlines. The text provides practical tips for managing time effectively, such as using time-blocking techniques, delegating tasks, and minimizing distractions. It also discusses the benefits of taking regular breaks and maintaining a healthy work-life balance.

4. The final section discusses the importance of continuous learning and professional development. It encourages individuals to stay up-to-date with the latest industry trends and technologies. The text provides suggestions for finding learning opportunities, such as attending conferences, taking courses, and seeking mentorship. It also emphasizes the importance of applying new knowledge and skills to the workplace to drive innovation and growth.

1. The first step in the process of identifying a potential target is to determine the target's location. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's location is identified, the next step is to determine the target's identity.

2. The second step in the process is to determine the target's identity. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's identity is identified, the next step is to determine the target's capabilities.

3. The third step in the process is to determine the target's capabilities. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's capabilities are identified, the next step is to determine the target's vulnerabilities.

4. The fourth step in the process is to determine the target's vulnerabilities. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's vulnerabilities are identified, the next step is to determine the target's weaknesses.

5. The fifth step in the process is to determine the target's weaknesses. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's weaknesses are identified, the next step is to determine the target's strengths.

6. The sixth step in the process is to determine the target's strengths. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's strengths are identified, the next step is to determine the target's weaknesses.

7. The seventh step in the process is to determine the target's weaknesses. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's weaknesses are identified, the next step is to determine the target's strengths.

8. The eighth step in the process is to determine the target's strengths. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's strengths are identified, the next step is to determine the target's weaknesses.

9. The ninth step in the process is to determine the target's weaknesses. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's weaknesses are identified, the next step is to determine the target's strengths.

10. The tenth step in the process is to determine the target's strengths. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's strengths are identified, the next step is to determine the target's weaknesses.

11. The eleventh step in the process is to determine the target's weaknesses. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's weaknesses are identified, the next step is to determine the target's strengths.

12. The twelfth step in the process is to determine the target's strengths. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's strengths are identified, the next step is to determine the target's weaknesses.

13. The thirteenth step in the process is to determine the target's weaknesses. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's weaknesses are identified, the next step is to determine the target's strengths.

14. The fourteenth step in the process is to determine the target's strengths. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's strengths are identified, the next step is to determine the target's weaknesses.

15. The fifteenth step in the process is to determine the target's weaknesses. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's weaknesses are identified, the next step is to determine the target's strengths.

16. The sixteenth step in the process is to determine the target's strengths. This is typically done by using a combination of satellite imagery and ground-based reconnaissance. Once the target's strengths are identified, the next step is to determine the target's weaknesses.

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

[illegible]

Figure 1. The structure of the proposed model.

^a Present address: A.S.M.E., 70 Collins, Bldg Comp Ltd Research Unit,
London EC2A 4DP, England.

[illegible][illegible][illegible][illegible]

Stat. Sci. 1997, Vol. 12, No. 3, 343-358. Printed in the USA.

[illegible]

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

...the ...
...the ...
...the ...

[illegible]

1. *Source* - the source of the data, e.g. a file, a database, a web page, a sensor, etc.
 2. *Destination* - the destination of the data, e.g. a file, a database, a web page, a sensor, etc.
 3. *Method* - the method used to transfer the data, e.g. HTTP, FTP, SMTP, etc.
 4. *Format* - the format of the data, e.g. JSON, XML, CSV, etc.
 5. *Frequency* - the frequency of the data transfer, e.g. once, hourly, daily, etc.
 6. *Size* - the size of the data, e.g. 1MB, 1GB, etc.
 7. *Priority* - the priority of the data transfer, e.g. low, medium, high, etc.
 8. *Authentication* - the authentication method used to transfer the data, e.g. basic, digest, etc.
 9. *Encryption* - the encryption method used to transfer the data, e.g. SSL, TLS, etc.
 10. *Compression* - the compression method used to transfer the data, e.g. gzip, deflate, etc.
 11. *Timeout* - the timeout value for the data transfer, e.g. 30s, 60s, etc.
 12. *Retry* - the number of times to retry the data transfer, e.g. 1, 3, 5, etc.
 13. *Log* - whether to log the data transfer, e.g. yes, no, etc.
 14. *Verbose* - whether to show verbose output for the data transfer, e.g. yes, no, etc.
 15. *Help* - whether to show the help message, e.g. yes, no, etc.

[illegible][illegible]

It is also important to note that the results predicted by equation (1) have a theoretical basis. The results are consistent with the idea that the degree of the genetic bottleneck, and the number of generations since the population was founded, are important factors in determining the genetic structure of a population.

[illegible]

00 TITLE OF INVENTION: INVENTION FOR THE USE OF INVENTION N. A.
 01 TITLE OF INVENTION: INVENTION FOR THE USE OF INVENTION N. A.
 02 NUMBER OF SEQUENCES: 2
 03 COUNTRY OF ORIGIN: U.S.A.
 04 ADDRESS: NIXON & VAN BUREN, INC.
 05 STREET: 110 NORTH GARDEN BLVD.
 06 CITY: ARLINGTON
 07 STATE: VIRGINIA
 08 COUNTRY: U.S.A.
 09 ZIP: 22201-4711
 10 COMPUTER AVAILABLE FROM:
 11 MEDIAN: YES
 12 MEDIUM: YES
 13 OPERATING SYSTEM: FOR SEQUENCES
 14 SOFTWARE: FOR SEQUENCES
 15 CURRENT APPLICATION DATA:
 16 APPLICATION NUMBER: 11/11/11
 17 FILING DATE: 11/11/11
 18 CLASS: 11/11/11
 19 AUTOMATIC/GENERAL INFORMATION:
 20 NAME: NIXON & VAN BUREN, INC.
 21 REGISTRATION NUMBER: 11/11/11
 22 REFERENCE/WORK NUMBER: 11/11/11
 23 TELECOMMUNICATION INFORMATION:
 24 TELEPHONE: (703) 916-1111
 25 FAX: (703) 916-1111
 26 INFORMATION IN SEQ. ID NO. 1:
 27 SEQUENCE CHARACTERISTICS:
 28 LENGTH: 11/11/11
 29 TYPE: YES
 30 STRANDNESS: 11/11/11
 31 MAINTENANCE: 11/11/11
 32 SEQUENCE: 11/11/11
 33 Query Match
 34 First Occurrence: 11/11/11
 35 Matches: 11/11/11
 36
 37 11/11/11
 38 11/11/11
 39
 40 RESULT 11
 41 US 11-11/11-11/11 STANDARDS: 11/11/11
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 47



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000



 Release 4.1A John F. Collins, Biocompare Research Unit,
 Department of Computer Science, University of Edinburgh, U.K.
 Distribution rights by Oxford Molecular Ltd

 Release 4.1A John F. Collins, Biocompare Research Unit,
 Department of Computer Science, University of Edinburgh, U.K.
 Distribution rights by Oxford Molecular Ltd

 Release 4.1A John F. Collins, Biocompare Research Unit,
 Department of Computer Science, University of Edinburgh, U.K.
 Distribution rights by Oxford Molecular Ltd

 Release 4.1A John F. Collins, Biocompare Research Unit,
 Department of Computer Science, University of Edinburgh, U.K.
 Distribution rights by Oxford Molecular Ltd

 Release 4.1A John F. Collins, Biocompare Research Unit,
 Department of Computer Science, University of Edinburgh, U.K.
 Distribution rights by Oxford Molecular Ltd

 Release 4.1A John F. Collins, Biocompare Research Unit,
 Department of Computer Science, University of Edinburgh, U.K.
 Distribution rights by Oxford Molecular Ltd

 Release 4.1A John F. Collins, Biocompare Research Unit,
 Department of Computer Science, University of Edinburgh, U.K.
 Distribution rights by Oxford Molecular Ltd

 Release 4.1A John F. Collins, Biocompare Research Unit,
 Department of Computer Science, University of Edinburgh, U.K.
 Distribution rights by Oxford Molecular Ltd

ALIGNMENTS

RESULT 1
 ID P50291 standard: Protein: 74 AA.
 AC P5291:
 CE Sequence enclosed by second exon of rabies glycoprotein gene.
 KW Rabies vaccine; therapy: glycoprotein; antigen: diaminol.
 RN W09501516-A.
 RF 02-APR-1985.
 RA (LATV) LAIBB 9.
 RI Latvian, Kibay AP, Lomonov V, Lomonov G, Alarie M.
 DR WP: 85-098845.16.
 ER N-PSDB: N50313.
 FT Vector for expressing rabies antigen - in eucaryotic cells.
 PT Useful for making vaccines and curative agents.
 PS Example: F11 (1-42pp): French.
 SC The inventors claim a vector for expressing a rabies antigen, having
 CC at ASP residues 244 and 419, the recombinant antigen protein is
 CC useful as a vaccine or curative agent. The coding sequence in the
 CC vector can be followed by an insertion (see Nucleic Acids) or stop at
 CC polyadenylation.
 SE Sequence 74 AA:

Query Match 100.0% Score 74.00 E-38 Identical 74
 Exact local similarity 100.0% Pos. No. 1-74
 Matches 7: Conservative 1: Mismatches 1: Gaps 1

18 5 YPWH11
 20 1 YPWH10


RESULT 2
 ID W73362 standard: Protein: 144 AA.

SUMMARY

| No. | Seq. | Match | Score | Description | Pred. No. |
|-----|------|-------|-------|------------------------|-----------|
| 1 | 1 | 74 | 100.0 | Sequence enclosed by 5 | 1-626-00 |
| 2 | 2 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 3 | 3 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 4 | 4 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 5 | 5 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 6 | 6 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 7 | 7 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 8 | 8 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 9 | 9 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 10 | 10 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 11 | 11 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 12 | 12 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 13 | 13 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 14 | 14 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 15 | 15 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 16 | 16 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 17 | 17 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 18 | 18 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 19 | 19 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 20 | 20 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 21 | 21 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 22 | 22 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 23 | 23 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 24 | 24 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 25 | 25 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 26 | 26 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 27 | 27 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 28 | 28 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 29 | 29 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 30 | 30 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 31 | 31 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 32 | 32 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 33 | 33 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 34 | 34 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 35 | 35 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 36 | 36 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 37 | 37 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 38 | 38 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 39 | 39 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 40 | 40 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 41 | 41 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 42 | 42 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 43 | 43 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 44 | 44 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |
| 45 | 45 | 144 | 99.9 | Human haemoglobin bet | 1-626-00 |

Note: No. is the number of residues predicted by chance to have a
 given number of matches to the score of the result being printed.
 It is derived by analysis of the total score distribution.





Amplitude (V) vs Time (sec) Plot
The plot shows the amplitude of the signal over time. The signal is noisy and shows a general upward trend.

Time (sec) vs Amplitude (V) Plot
The plot shows the time of the signal over amplitude. The signal is noisy and shows a general downward trend.

Time (sec) vs Amplitude (V) Plot
The plot shows the time of the signal over amplitude. The signal is noisy and shows a general downward trend.

Time (sec) vs Amplitude (V) Plot
The plot shows the time of the signal over amplitude. The signal is noisy and shows a general downward trend.

Time (sec) vs Amplitude (V) Plot
The plot shows the time of the signal over amplitude. The signal is noisy and shows a general downward trend.

Time (sec) vs Amplitude (V) Plot
The plot shows the time of the signal over amplitude. The signal is noisy and shows a general downward trend.

Time (sec) vs Amplitude (V) Plot
The plot shows the time of the signal over amplitude. The signal is noisy and shows a general downward trend.

Time (sec) vs Amplitude (V) Plot
The plot shows the time of the signal over amplitude. The signal is noisy and shows a general downward trend.

Time (sec) vs Amplitude (V) Plot
The plot shows the time of the signal over amplitude. The signal is noisy and shows a general downward trend.

Time (sec) vs Amplitude (V) Plot
The plot shows the time of the signal over amplitude. The signal is noisy and shows a general downward trend.

APPENDICES

| Appendix | Time (sec) | Amplitude (V) | Frequency (Hz) | Phase (deg) |
|----------|------------|---------------|----------------|-------------|
| 1 | 0.0 | 0.0 | 0.0 | 0.0 |
| 2 | 0.1 | 0.8 | 0.0 | 0.0 |
| 3 | 0.2 | 0.8 | 0.0 | 0.0 |
| 4 | 0.3 | 0.2 | 0.0 | 0.0 |
| 5 | 0.4 | 0.2 | 0.0 | 0.0 |
| 6 | 0.5 | 0.6 | 0.0 | 0.0 |
| 7 | 0.6 | 0.6 | 0.0 | 0.0 |
| 8 | 0.7 | 0.6 | 0.0 | 0.0 |
| 9 | 0.8 | 0.6 | 0.0 | 0.0 |
| 10 | 0.9 | 0.6 | 0.0 | 0.0 |
| 11 | 1.0 | 0.6 | 0.0 | 0.0 |



1 01:11:11 PM N.A.
2 01:11:11 PM N.A.
3 01:11:11 PM N.A.
4 01:11:11 PM N.A.
5 01:11:11 PM N.A.
6 01:11:11 PM N.A.
7 01:11:11 PM N.A.
8 01:11:11 PM N.A.
9 01:11:11 PM N.A.
10 01:11:11 PM N.A.
11 01:11:11 PM N.A.
12 01:11:11 PM N.A.
13 01:11:11 PM N.A.
14 01:11:11 PM N.A.
15 01:11:11 PM N.A.
16 01:11:11 PM N.A.
17 01:11:11 PM N.A.
18 01:11:11 PM N.A.
19 01:11:11 PM N.A.
20 01:11:11 PM N.A.
21 01:11:11 PM N.A.
22 01:11:11 PM N.A.
23 01:11:11 PM N.A.
24 01:11:11 PM N.A.
25 01:11:11 PM N.A.
26 01:11:11 PM N.A.
27 01:11:11 PM N.A.
28 01:11:11 PM N.A.
29 01:11:11 PM N.A.
30 01:11:11 PM N.A.
31 01:11:11 PM N.A.
32 01:11:11 PM N.A.
33 01:11:11 PM N.A.
34 01:11:11 PM N.A.
35 01:11:11 PM N.A.
36 01:11:11 PM N.A.
37 01:11:11 PM N.A.
38 01:11:11 PM N.A.
39 01:11:11 PM N.A.
40 01:11:11 PM N.A.
41 01:11:11 PM N.A.
42 01:11:11 PM N.A.
43 01:11:11 PM N.A.
44 01:11:11 PM N.A.
45 01:11:11 PM N.A.
46 01:11:11 PM N.A.
47 01:11:11 PM N.A.
48 01:11:11 PM N.A.
49 01:11:11 PM N.A.
50 01:11:11 PM N.A.
51 01:11:11 PM N.A.
52 01:11:11 PM N.A.
53 01:11:11 PM N.A.
54 01:11:11 PM N.A.
55 01:11:11 PM N.A.
56 01:11:11 PM N.A.
57 01:11:11 PM N.A.
58 01:11:11 PM N.A.
59 01:11:11 PM N.A.
60 01:11:11 PM N.A.
61 01:11:11 PM N.A.
62 01:11:11 PM N.A.
63 01:11:11 PM N.A.
64 01:11:11 PM N.A.
65 01:11:11 PM N.A.
66 01:11:11 PM N.A.
67 01:11:11 PM N.A.
68 01:11:11 PM N.A.
69 01:11:11 PM N.A.
70 01:11:11 PM N.A.
71 01:11:11 PM N.A.
72 01:11:11 PM N.A.
73 01:11:11 PM N.A.
74 01:11:11 PM N.A.
75 01:11:11 PM N.A.
76 01:11:11 PM N.A.
77 01:11:11 PM N.A.
78 01:11:11 PM N.A.
79 01:11:11 PM N.A.
80 01:11:11 PM N.A.
81 01:11:11 PM N.A.
82 01:11:11 PM N.A.
83 01:11:11 PM N.A.
84 01:11:11 PM N.A.
85 01:11:11 PM N.A.
86 01:11:11 PM N.A.
87 01:11:11 PM N.A.
88 01:11:11 PM N.A.
89 01:11:11 PM N.A.
90 01:11:11 PM N.A.
91 01:11:11 PM N.A.
92 01:11:11 PM N.A.
93 01:11:11 PM N.A.
94 01:11:11 PM N.A.
95 01:11:11 PM N.A.
96 01:11:11 PM N.A.
97 01:11:11 PM N.A.
98 01:11:11 PM N.A.
99 01:11:11 PM N.A.
100 01:11:11 PM N.A.






Figure 1: A graph showing the results of the experiment. The x-axis is labeled 'Time' and the y-axis is labeled 'Amplitude'. The graph shows a series of peaks, with the highest peak reaching an amplitude of approximately 1.0. The peaks are labeled with numbers 1 through 10. The graph is titled 'Figure 1: A graph showing the results of the experiment.'

Figure 2: A graph showing the results of the experiment. The x-axis is labeled 'Time' and the y-axis is labeled 'Amplitude'. The graph shows a series of peaks, with the highest peak reaching an amplitude of approximately 1.0. The peaks are labeled with numbers 1 through 10. The graph is titled 'Figure 2: A graph showing the results of the experiment.'

Figure 3: A graph showing the results of the experiment. The x-axis is labeled 'Time' and the y-axis is labeled 'Amplitude'. The graph shows a series of peaks, with the highest peak reaching an amplitude of approximately 1.0. The peaks are labeled with numbers 1 through 10. The graph is titled 'Figure 3: A graph showing the results of the experiment.'

Figure 4: A graph showing the results of the experiment. The x-axis is labeled 'Time' and the y-axis is labeled 'Amplitude'. The graph shows a series of peaks, with the highest peak reaching an amplitude of approximately 1.0. The peaks are labeled with numbers 1 through 10. The graph is titled 'Figure 4: A graph showing the results of the experiment.'

Figure 5: A graph showing the results of the experiment. The x-axis is labeled 'Time' and the y-axis is labeled 'Amplitude'. The graph shows a series of peaks, with the highest peak reaching an amplitude of approximately 1.0. The peaks are labeled with numbers 1 through 10. The graph is titled 'Figure 5: A graph showing the results of the experiment.'

Figure 6: A graph showing the results of the experiment. The x-axis is labeled 'Time' and the y-axis is labeled 'Amplitude'. The graph shows a series of peaks, with the highest peak reaching an amplitude of approximately 1.0. The peaks are labeled with numbers 1 through 10. The graph is titled 'Figure 6: A graph showing the results of the experiment.'

Figure 7: A graph showing the results of the experiment. The x-axis is labeled 'Time' and the y-axis is labeled 'Amplitude'. The graph shows a series of peaks, with the highest peak reaching an amplitude of approximately 1.0. The peaks are labeled with numbers 1 through 10. The graph is titled 'Figure 7: A graph showing the results of the experiment.'

| Time | Amplitude | Description | Prod. No. |
|------|-----------|-------------|-----------|
| 1.0 | 0.5 | Human | 1.0 |
| 2.0 | 0.5 | Human | 1.0 |
| 3.0 | 0.5 | Human | 1.0 |
| 4.0 | 0.5 | Human | 1.0 |
| 5.0 | 0.5 | Human | 1.0 |
| 6.0 | 0.5 | Human | 1.0 |
| 7.0 | 0.5 | Human | 1.0 |
| 8.0 | 0.5 | Human | 1.0 |
| 9.0 | 0.5 | Human | 1.0 |
| 10.0 | 0.5 | Human | 1.0 |

1. The following information was obtained from the records of the
Bureau of the Census, Department of Commerce, Bureau of Economic
Analysis, Office of Statistics, Washington, D.C., on November 15, 1999:

1. The following information was obtained from the records of the
Bureau of the Census, Department of Commerce, Bureau of Economic
Analysis, Office of Statistics, Washington, D.C., on November 15, 1999:

1. The following information was obtained from the records of the
Bureau of the Census, Department of Commerce, Bureau of Economic
Analysis, Office of Statistics, Washington, D.C., on November 15, 1999:



4.2. *Effect of the type of the substrate*

The effect of the type of the substrate on the growth of *S. aureus* is shown in Figure 2. The growth of *S. aureus* was significantly higher on the substrate of 100% *Agarose* than on the substrate of 100% *Agar* ($P < 0.05$). The growth of *S. aureus* was significantly higher on the substrate of 100% *Agarose* than on the substrate of 100% *Agar* ($P < 0.05$). The growth of *S. aureus* was significantly higher on the substrate of 100% *Agarose* than on the substrate of 100% *Agar* ($P < 0.05$).

1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 26

There is a large number of people who are not interested in the results of the election, but who are interested in the results of the election, and who are interested in the results of the election.

| Country | Year | Population (millions) | Urban population (millions) | Urban population (%) | Population density (per sq km) | Urban population density (per sq km) |
|---------|------|-----------------------|-----------------------------|----------------------|--------------------------------|--------------------------------------|
| Algeria | 1980 | 10.0 | 4.0 | 40.0 | 100 | 400 |
| Algeria | 1985 | 10.5 | 4.5 | 42.9 | 105 | 429 |
| Algeria | 1990 | 11.0 | 5.0 | 45.5 | 110 | 455 |
| Algeria | 1995 | 11.5 | 5.5 | 47.8 | 115 | 478 |
| Algeria | 2000 | 12.0 | 6.0 | 50.0 | 120 | 500 |
| Algeria | 2005 | 12.5 | 6.5 | 52.0 | 125 | 520 |
| Algeria | 2010 | 13.0 | 7.0 | 53.8 | 130 | 538 |
| Algeria | 2015 | 13.5 | 7.5 | 55.6 | 135 | 556 |
| Algeria | 2020 | 14.0 | 8.0 | 57.1 | 140 | 571 |
| Algeria | 2025 | 14.5 | 8.5 | 58.6 | 145 | 586 |
| Algeria | 2030 | 15.0 | 9.0 | 60.0 | 150 | 600 |
| Algeria | 2035 | 15.5 | 9.5 | 61.3 | 155 | 613 |
| Algeria | 2040 | 16.0 | 10.0 | 62.5 | 160 | 625 |
| Algeria | 2045 | 16.5 | 10.5 | 63.6 | 165 | 636 |
| Algeria | 2050 | 17.0 | 11.0 | 64.7 | 170 | 647 |
| Algeria | 2055 | 17.5 | 11.5 | 65.7 | 175 | 657 |
| Algeria | 2060 | 18.0 | 12.0 | 66.7 | 180 | 667 |
| Algeria | 2065 | 18.5 | 12.5 | 67.6 | 185 | 676 |
| Algeria | 2070 | 19.0 | 13.0 | 68.4 | 190 | 684 |
| Algeria | 2075 | 19.5 | 13.5 | 69.2 | 195 | 692 |
| Algeria | 2080 | 20.0 | 14.0 | 70.0 | 200 | 700 |
| Algeria | 2085 | 20.5 | 14.5 | 70.7 | 205 | 707 |
| Algeria | 2090 | 21.0 | 15.0 | 71.4 | 210 | 714 |
| Algeria | 2095 | 21.5 | 15.5 | 72.1 | 215 | 721 |
| Algeria | 2100 | 22.0 | 16.0 | 72.7 | 220 | 727 |
| Algeria | 2105 | 22.5 | 16.5 | 73.3 | 225 | 733 |
| Algeria | 2110 | 23.0 | 17.0 | 73.9 | 230 | 739 |
| Algeria | 2115 | 23.5 | 17.5 | 74.5 | 235 | 745 |
| Algeria | 2120 | 24.0 | 18.0 | 75.0 | 240 | 750 |
| Algeria | 2125 | 24.5 | 18.5 | 75.5 | 245 | 755 |
| Algeria | 2130 | 25.0 | 19.0 | 76.0 | 250 | 760 |
| Algeria | 2135 | 25.5 | 19.5 | 76.5 | 255 | 765 |
| Algeria | 2140 | 26.0 | 20.0 | 76.9 | 260 | 769 |
| Algeria | 2145 | 26.5 | 20.5 | 77.4 | 265 | 774 |
| Algeria | 2150 | 27.0 | 21.0 | 77.8 | 270 | 778 |
| Algeria | 2155 | 27.5 | 21.5 | 78.2 | 275 | 782 |
| Algeria | 2160 | 28.0 | 22.0 | 78.6 | 280 | 786 |
| Algeria | 2165 | 28.5 | 22.5 | 78.9 | 285 | 789 |
| Algeria | 2170 | 29.0 | 23.0 | 79.3 | 290 | 793 |
| Algeria | 2175 | 29.5 | 23.5 | 79.7 | 295 | 797 |
| Algeria | 2180 | 30.0 | 24.0 | 80.0 | 300 | 800 |
| Algeria | 2185 | 30.5 | 24.5 | 80.3 | 305 | 803 |
| Algeria | 2190 | 31.0 | 25.0 | 80.6 | 310 | 806 |
| Algeria | 2195 | 31.5 | 25.5 | 81.0 | 315 | 810 |
| Algeria | 2200 | 32.0 | 26.0 | 81.3 | 320 | 813 |
| Algeria | 2205 | 32.5 | 26.5 | 81.6 | 325 | 816 |
| Algeria | 2210 | 33.0 | 27.0 | 81.8 | 330 | 818 |
| Algeria | 2215 | 33.5 | 27.5 | 82.1 | 335 | 821 |
| Algeria | 2220 | 34.0 | 28.0 | 82.4 | 340 | 824 |
| Algeria | 2225 | 34.5 | 28.5 | 82.6 | 345 | 826 |
| Algeria | 2230 | 35.0 | 29.0 | 82.9 | 350 | 829 |
| Algeria | 2235 | 35.5 | 29.5 | 83.1 | 355 | 831 |
| Algeria | 2240 | 36.0 | 30.0 | 83.3 | 360 | 833 |
| Algeria | 2245 | 36.5 | 30.5 | 83.6 | 365 | 836 |
| Algeria | 2250 | | | | | |

[illegible]

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 117 | 118 | 119 | 120 | 121 | 122 | 123 | 124 | 125 | 126 | 127 | 128 | 129 | 130 | 131 | 132 | 133 | 134 | 135 | 136 | 137 | 138 | 139 | 140 | 141 | 142 | 143 | 144 | 145 | 146 | 147 | 148 | 149 | 150 | 151 | 152 | 153 | 154 | 155 | 156 | 157 | 158 | 159 | 160 | 161 | 162 | 163 | 164 | 165 | 166 | 167 | 168 | 169 | 170 | 171 | 172 | 173 | 174 | 175 | 176 | 177 | 178 | 179 | 180 | 181 | 182 | 183 | 184 | 185 | 186 | 187 | 188 | 189 | 190 | 191 | 192 | 193 | 194 | 195 | 196 | 197 | 198 | 199 | 200 | 201 | 202 | 203 | 204 | 205 | 206 | 207 | 208 | 209 | 210 | 211 | 212 | 213 | 214 | 215 | 216 | 217 | 218 | 219 | 220 | 221 | 222 | 223 | 224 | 225 | 226 | 227 | 228 | 229 | 230 | 231 | 232 | 233 | 234 | 235 | 236 | 237 | 238 | 239 | 240 | 241 | 242 | 243 | 244 | 245 | 246 | 247 | 248 | 249 | 250 | 251 | 252 | 253 | 254 | 255 | 256 | 257 | 258 | 259 | 260 | 261 | 262 | 263 | 264 | 265 | 266 | 267 | 268 | 269 | 270 | 271 | 272 | 273 | 274 | 275 | 276 | 277 | 278 | 279 | 280 | 281 | 282 | 283 | 284 | 285 | 286 | 287 | 288 | 289 | 290 | 291 | 292 | 293 | 294 | 295 | 296 | 297 | 298 | 299 | 300 | 301 | 302 | 303 | 304 | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 | 314 | 315 | 316 | 317 | 318 | 319 | 320 | 321 | 322 | 323 | 324 | 325 | 326 | 327 | 328 | 329 | 330 | 331 | 332 | 333 | 334 | 335 | 336 | 337 | 338 | 339 | 340 | 341 | 342 | 343 | 344 | 345 | 346 | 347 | 348 | 349 | 350 | 351 | 352 | 353 | 354 | 355 | 356 | 357 | 358 | 359 | 360 | 361 | 362 | 363 | 364 | 365 | 366 | 367 | 368 | 369 | 370 | 371 | 372 | 373 | 374 | 375 | 376 | 377 | 378 | 379 | 380 | 381 | 382 | 383 | 384 | 385 | 386 | 387 | 388 | 389 | 390 | 391 | 392 | 393 | 394 | 395 | 396 | 397 | 398 | 399 | 400 | 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 | 409 | 410 | 411 | 412 | 413 | 414 | 415 | 416 | 417 | 418 | 419 | 420 | 421 | 422 | 423 | 424 | 425 | 426 | 427 | 428 | 429 | 430 | 431 | 432 | 433 | 434 | 435 | 436 | 437 | 438 | 439 | 440 | 441 | 442 | 443 | 444 | 445 | 446 | 447 | 448 | 449 | 450 | 451 | 452 | 453 | 454 | 455 | 456 | 457 | 458 | 459 | 460 | 461 | 462 | 463 | 464 | 465 | 466 | 467 | 468 | 469 | 470 | 471 | 472 | 473 | 474 | 475 | 476 | 477 | 478 | 479 | 480 | 481 | 482 | 483 | 484 | 485 | 486 | 487 | 488 | 489 | 490 | 491 | 492 | 493 | 494 | 495 | 496 | 497 | 498 | 499 | 500 | 501 | 502 | 503 | 504 | 505 | 506 | 507 | 508 | 509 | 510 | 511 | 512 | 513 | 514 | 515 | 516 | 517 | 518 | 519 | 520 | 521 | 522 | 523 | 52 |
|--|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
|--|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|

[illegible]

[illegible][illegible][illegible][illegible][illegible][illegible][illegible]

[illegible][illegible]

100

KR Best cloning strategy: human cDNA library (kind product) cDNA library (kind)
 KR 1. cDNA library
 KR 2. cDNA library
 KR 3. cDNA library
 KR 4. cDNA library
 KR 5. cDNA library
 KR 6. cDNA library
 KR 7. cDNA library
 KR 8. cDNA library
 KR 9. cDNA library
 KR 10. cDNA library
 KR 11. cDNA library
 KR 12. cDNA library
 KR 13. cDNA library
 KR 14. cDNA library
 KR 15. cDNA library
 KR 16. cDNA library
 KR 17. cDNA library
 KR 18. cDNA library
 KR 19. cDNA library
 KR 20. cDNA library
 KR 21. cDNA library
 KR 22. cDNA library
 KR 23. cDNA library
 KR 24. cDNA library
 KR 25. cDNA library
 KR 26. cDNA library
 KR 27. cDNA library
 KR 28. cDNA library
 KR 29. cDNA library
 KR 30. cDNA library
 KR 31. cDNA library
 KR 32. cDNA library
 KR 33. cDNA library
 KR 34. cDNA library
 KR 35. cDNA library
 KR 36. cDNA library
 KR 37. cDNA library
 KR 38. cDNA library
 KR 39. cDNA library
 KR 40. cDNA library
 KR 41. cDNA library
 KR 42. cDNA library
 KR 43. cDNA library
 KR 44. cDNA library
 KR 45. cDNA library
 KR 46. cDNA library
 KR 47. cDNA library
 KR 48. cDNA library
 KR 49. cDNA library
 KR 50. cDNA library
 KR 51. cDNA library
 KR 52. cDNA library
 KR 53. cDNA library
 KR 54. cDNA library
 KR 55. cDNA library
 KR 56. cDNA library
 KR 57. cDNA library
 KR 58. cDNA library
 KR 59. cDNA library
 KR 60. cDNA library
 KR 61. cDNA library
 KR 62. cDNA library
 KR 63. cDNA library
 KR 64. cDNA library
 KR 65. cDNA library
 KR 66. cDNA library
 KR 67. cDNA library
 KR 68. cDNA library
 KR 69. cDNA library
 KR 70. cDNA library
 KR 71. cDNA library
 KR 72. cDNA library
 KR 73. cDNA library
 KR 74. cDNA library
 KR 75. cDNA library
 KR 76. cDNA library
 KR 77. cDNA library
 KR 78. cDNA library
 KR 79. cDNA library
 KR 80. cDNA library
 KR 81. cDNA library
 KR 82. cDNA library
 KR 83. cDNA library
 KR 84. cDNA library
 KR 85. cDNA library
 KR 86. cDNA library
 KR 87. cDNA library
 KR 88. cDNA library
 KR 89. cDNA library
 KR 90. cDNA library
 KR 91. cDNA library
 KR 92. cDNA library
 KR 93. cDNA library
 KR 94. cDNA library
 KR 95. cDNA library
 KR 96. cDNA library
 KR 97. cDNA library
 KR 98. cDNA library
 KR 99. cDNA library
 KR 100. cDNA library

KR 101. cDNA library
 KR 102. cDNA library
 KR 103. cDNA library
 KR 104. cDNA library
 KR 105. cDNA library
 KR 106. cDNA library
 KR 107. cDNA library
 KR 108. cDNA library
 KR 109. cDNA library
 KR 110. cDNA library
 KR 111. cDNA library
 KR 112. cDNA library
 KR 113. cDNA library
 KR 114. cDNA library
 KR 115. cDNA library
 KR 116. cDNA library
 KR 117. cDNA library
 KR 118. cDNA library
 KR 119. cDNA library
 KR 120. cDNA library
 KR 121. cDNA library
 KR 122. cDNA library
 KR 123. cDNA library
 KR 124. cDNA library
 KR 125. cDNA library
 KR 126. cDNA library
 KR 127. cDNA library
 KR 128. cDNA library
 KR 129. cDNA library
 KR 130. cDNA library
 KR 131. cDNA library
 KR 132. cDNA library
 KR 133. cDNA library
 KR 134. cDNA library
 KR 135. cDNA library
 KR 136. cDNA library
 KR 137. cDNA library
 KR 138. cDNA library
 KR 139. cDNA library
 KR 140. cDNA library
 KR 141. cDNA library
 KR 142. cDNA library
 KR 143. cDNA library
 KR 144. cDNA library
 KR 145. cDNA library
 KR 146. cDNA library
 KR 147. cDNA library
 KR 148. cDNA library
 KR 149. cDNA library
 KR 150. cDNA library
 KR 151. cDNA library
 KR 152. cDNA library
 KR 153. cDNA library
 KR 154. cDNA library
 KR 155. cDNA library
 KR 156. cDNA library
 KR 157. cDNA library
 KR 158. cDNA library
 KR 159. cDNA library
 KR 160. cDNA library
 KR 161. cDNA library
 KR 162. cDNA library
 KR 163. cDNA library
 KR 164. cDNA library
 KR 165. cDNA library
 KR 166. cDNA library
 KR 167. cDNA library
 KR 168. cDNA library
 KR 169. cDNA library
 KR 170. cDNA library
 KR 171. cDNA library
 KR 172. cDNA library
 KR 173. cDNA library
 KR 174. cDNA library
 KR 175. cDNA library
 KR 176. cDNA library
 KR 177. cDNA library
 KR 178. cDNA library
 KR 179. cDNA library
 KR 180. cDNA library
 KR 181. cDNA library
 KR 182. cDNA library
 KR 183. cDNA library
 KR 184. cDNA library
 KR 185. cDNA library
 KR 186. cDNA library
 KR 187. cDNA library
 KR 188. cDNA library
 KR 189. cDNA library
 KR 190. cDNA library
 KR 191. cDNA library
 KR 192. cDNA library
 KR 193. cDNA library
 KR 194. cDNA library
 KR 195. cDNA library
 KR 196. cDNA library
 KR 197. cDNA library
 KR 198. cDNA library
 KR 199. cDNA library
 KR 200. cDNA library

[illegible]

© 1996 by John Wiley & Sons, Inc. All rights reserved. This publication is registered at the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923. Organizations in the U.S. who are also registered with C.C.C. may therefore copy material (beyond the limits permitted by sections 107 and 108 of U.S. copyright law) subject to payment to C.C.C. of the per copy fee of \$05.00. This consent does not extend to multiple copying for promotional or commercial purposes. ISI Tear Sheet Service, 3501 Market Street, Philadelphia, PA 19104, USA, is authorized to supply single copies of separate articles for private use only. Organizations authorized by the Copyright Licensing Agency may also copy material subject to the usual conditions. For all other use, permission should be sought from John Wiley & Sons, Inc. This journal is registered at the Library of Congress. Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923. Organizations in the U.S. who are also registered with C.C.C. may therefore copy material (beyond the limits permitted by sections 107 and 108 of U.S. copyright law) subject to payment to C.C.C. of the per copy fee of \$05.00. This consent does not extend to multiple copying for promotional or commercial purposes. *Printed in the United States of America*

| 項目 | 単位 | 数値 | 単位 | 数値 | |
|------------|----|-----------|-------------|----|---------|
| 1. 総人口 | 人 | 1,234,567 | 2. 男性人口 | 人 | 612,345 |
| 3. 女性人口 | 人 | 622,222 | 4. 0歳人口 | 人 | 15,678 |
| 5. 1歳人口 | 人 | 14,567 | 6. 2歳人口 | 人 | 13,456 |
| 7. 3歳人口 | 人 | 12,345 | 8. 4歳人口 | 人 | 11,234 |
| 9. 5歳人口 | 人 | 10,123 | 10. 6歳人口 | 人 | 9,012 |
| 11. 7歳人口 | 人 | 8,901 | 12. 8歳人口 | 人 | 7,890 |
| 13. 9歳人口 | 人 | 6,789 | 14. 10歳人口 | 人 | 5,678 |
| 15. 11歳人口 | 人 | 4,567 | 16. 12歳人口 | 人 | 3,456 |
| 17. 13歳人口 | 人 | 2,345 | 18. 14歳人口 | 人 | 1,234 |
| 19. 15歳人口 | 人 | 1,123 | 20. 16歳人口 | 人 | 1,012 |
| 21. 17歳人口 | 人 | 901 | 22. 18歳人口 | 人 | 890 |
| 23. 19歳人口 | 人 | 789 | 24. 20歳人口 | 人 | 678 |
| 25. 21歳人口 | 人 | 567 | 26. 22歳人口 | 人 | 456 |
| 27. 23歳人口 | 人 | 345 | 28. 24歳人口 | 人 | 234 |
| 29. 25歳人口 | 人 | 123 | 30. 26歳人口 | 人 | 112 |
| 31. 27歳人口 | 人 | 101 | 32. 28歳人口 | 人 | 90 |
| 33. 29歳人口 | 人 | 89 | 34. 30歳人口 | 人 | 78 |
| 35. 31歳人口 | 人 | 67 | 36. 32歳人口 | 人 | 56 |
| 37. 33歳人口 | 人 | 45 | 38. 34歳人口 | 人 | 34 |
| 39. 35歳人口 | 人 | 23 | 40. 36歳人口 | 人 | 12 |
| 41. 37歳人口 | 人 | 11 | 42. 38歳人口 | 人 | 10 |
| 43. 39歳人口 | 人 | 9 | 44. 40歳人口 | 人 | 8 |
| 45. 41歳人口 | 人 | 7 | 46. 42歳人口 | 人 | 6 |
| 47. 43歳人口 | 人 | 5 | 48. 44歳人口 | 人 | 4 |
| 49. 45歳人口 | 人 | 3 | 50. 46歳人口 | 人 | 2 |
| 51. 47歳人口 | 人 | 1 | 52. 48歳人口 | 人 | 1 |
| 53. 49歳人口 | 人 | 1 | 54. 50歳人口 | 人 | 1 |
| 55. 51歳人口 | 人 | 1 | 56. 52歳人口 | 人 | 1 |
| 57. 53歳人口 | 人 | 1 | 58. 54歳人口 | 人 | 1 |
| 59. 55歳人口 | 人 | 1 | 60. 56歳人口 | 人 | 1 |
| 61. 57歳人口 | 人 | 1 | 62. 58歳人口 | 人 | 1 |
| 63. 59歳人口 | 人 | 1 | 64. 60歳人口 | 人 | 1 |
| 65. 61歳人口 | 人 | 1 | 66. 62歳人口 | 人 | 1 |
| 67. 63歳人口 | 人 | 1 | 68. 64歳人口 | 人 | 1 |
| 69. 65歳人口 | 人 | 1 | 70. 66歳人口 | 人 | 1 |
| 71. 67歳人口 | 人 | 1 | 72. 68歳人口 | 人 | 1 |
| 73. 69歳人口 | 人 | 1 | 74. 70歳人口 | 人 | 1 |
| 75. 71歳人口 | 人 | 1 | 76. 72歳人口 | 人 | 1 |
| 77. 73歳人口 | 人 | 1 | 78. 74歳人口 | 人 | 1 |
| 79. 75歳人口 | 人 | 1 | 80. 76歳人口 | 人 | 1 |
| 81. 77歳人口 | 人 | 1 | 82. 78歳人口 | 人 | 1 |
| 83. 79歳人口 | 人 | 1 | 84. 80歳人口 | 人 | 1 |
| 85. 81歳人口 | 人 | 1 | 86. 82歳人口 | 人 | 1 |
| 87. 83歳人口 | 人 | 1 | 88. 84歳人口 | 人 | 1 |
| 89. 85歳人口 | 人 | 1 | 90. 86歳人口 | 人 | 1 |
| 91. 87歳人口 | 人 | 1 | 92. 88歳人口 | 人 | 1 |
| 93. 89歳人口 | 人 | 1 | 94. 90歳人口 | 人 | 1 |
| 95. 91歳人口 | 人 | 1 | 96. 92歳人口 | 人 | 1 |
| 97. 93歳人口 | 人 | 1 | 98. 94歳人口 | 人 | 1 |
| 99. 95歳人口 | 人 | 1 | 100. 96歳人口 | 人 | 1 |
| 101. 97歳人口 | 人 | 1 | 102. 98歳人口 | 人 | 1 |
| 103. 99歳人口 | 人 | 1 | 104. 100歳人口 | 人 | 1 |

For the purpose of this study, the following hypotheses were formulated:

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 117 | 118 | 119 | 120 | 121 | 122 | 123 | 124 | 125 | 126 | 127 | 128 | 129 | 130 | 131 | 132 | 133 | 134 | 135 | 136 | 137 | 138 | 139 | 140 | 141 | 142 | 143 | 144 | 145 | 146 | 147 | 148 | 149 | 150 | 151 | 152 | 153 | 154 | 155 | 156 | 157 | 158 | 159 | 160 | 161 | 162 | 163 | 164 | 165 | 166 | 167 | 168 | 169 | 170 | 171 | 172 | 173 | 174 | 175 | 176 | 177 | 178 | 179 | 180 | 181 | 182 | 183 | 184 | 185 | 186 | 187 | 188 | 189 | 190 | 191 | 192 | 193 | 194 | 195 | 196 | 197 | 198 | 199 | 200 | 201 | 202 | 203 | 204 | 205 | 206 | 207 | 208 | 209 | 210 | 211 | 212 | 213 | 214 | 215 | 216 | 217 | 218 | 219 | 220 | 221 | 222 | 223 | 224 | 225 | 226 | 227 | 228 | 229 | 230 | 231 | 232 | 233 | 234 | 235 | 236 | 237 | 238 | 239 | 240 | 241 | 242 | 243 | 244 | 245 | 246 | 247 | 248 | 249 | 250 | 251 | 252 | 253 | 254 | 255 | 256 | 257 | 258 | 259 | 260 | 261 | 262 | 263 | 264 | 265 | 266 | 267 | 268 | 269 | 270 | 271 | 272 | 273 | 274 | 275 | 276 | 277 | 278 | 279 | 280 | 281 | 282 | 283 | 284 | 285 | 286 | 287 | 288 | 289 | 290 | 291 | 292 | 293 | 294 | 295 | 296 | 297 | 298 | 299 | 300 | 301 | 302 | 303 | 304 | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 | 314 | 315 | 316 | 317 | 318 | 319 | 320 | 321 | 322 | 323 | 324 | 325 | 326 | 327 | 328 | 329 | 330 | 331 | 332 | 333 | 334 | 335 | 336 | 337 | 338 | 339 | 340 | 341 | 342 | 343 | 344 | 345 | 346 | 347 | 348 | 349 | 350 | 351 | 352 | 353 | 354 | 355 | 356 | 357 | 358 | 359 | 360 | 361 | 362 | 363 | 364 | 365 | 366 | 367 | 368 | 369 | 370 | 371 | 372 | 373 | 374 | 375 | 376 | 377 | 378 | 379 | 380 | 381 | 382 | 383 | 384 | 385 | 386 | 387 | 388 | 389 | 390 | 391 | 392 | 393 | 394 | 395 | 396 | 397 | 398 | 399 | 400 | 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 | 409 | 410 | 411 | 412 | 413 | 414 | 415 | 416 | 417 | 418 | 419 | 420 | 421 | 422 | 423 | 424 | 425 | 426 | 427 | 428 | 429 | 430 | 431 | 432 | 433 | 434 | 435 | 436 | 437 | 438 | 439 | 440 | 441 | 442 | 443 | 444 | 445 | 446 | 447 | 448 | 449 | 450 | 451 | 452 | 453 | 454 | 455 | 456 | 457 | 458 | 459 | 460 | 461 | 462 | 463 | 464 | 465 | 466 | 467 | 468 | 469 | 470 | 471 | 472 | 473 | 474 | 475 | 476 | 477 | 478 | 479 | 480 | 481 | 482 | 483 | 484 | 485 | 486 | 487 | 488 | 489 | 490 | 491 | 492 | 493 | 494 | 495 | 496 | 497 | 498 | 499 | 500 | 501 | 502 | 503 | 504 | 505 | 506 | 507 | 508 | 509 | 510 | 511 | 512 | 513 | 514 | 515 | 516 | 517 | 518 | 519 | 520 | 521 | 522 | 523 | 524 | 5 |
|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|

SEQUENCE 11, Application US/8627173
PATENT NO. 5,149,383
GENERAL INFORMATION:
APPLICANT: TSYRGOVA, IRENA
TITLE OF INVENTION: INHIBITION OF STEM CELL PROLIFERATION AND
TITLE OF INVENTION: USER THEREOF
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHOF P.C.
STREET: 1100 NORTH GLEBE ROAD
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIA: 3.5" FLOPPY DISK
OPERATING SYSTEM: PC DOS/MS-DOS
SOFTWARE: Patent Release #103, Version #1.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: 08/324,173
FILING DATE: 03-APR-1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/324,173
FILING DATE: 03-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: BYRNE, THOMAS E.
REGISTRATION NUMBER: 42,205
TELEPHONE: (703) 816-4100
TELEFAX: (703) 816-4100
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: amino acids
TYPE: amino acid
STRATEGIES:
TOPOLGIC: linear
MOLECULE TYPE: polypeptide
SEQUENCE 7 AA: 502 HK, 411 DK
Gaps: 0

SEQUENCE 11, Application US/8627173
PATENT NO. 5,149,383
GENERAL INFORMATION:
APPLICANT: TSYRGOVA, IRENA
TITLE OF INVENTION: INHIBITION OF STEM CELL PROLIFERATION AND
TITLE OF INVENTION: USER THEREOF
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHOF P.C.
STREET: 1100 NORTH GLEBE ROAD
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIA: 3.5" FLOPPY DISK
OPERATING SYSTEM: PC DOS/MS-DOS
SOFTWARE: Patent Release #103, Version #1.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: 08/324,173
FILING DATE: 03-APR-1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/324,173
FILING DATE: 03-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: BYRNE, THOMAS E.
REGISTRATION NUMBER: 42,205
TELEPHONE: (703) 816-4100
TELEFAX: (703) 816-4100
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: amino acids
TYPE: amino acid
STRATEGIES:
TOPOLGIC: linear
MOLECULE TYPE: polypeptide
SEQUENCE 7 AA: 502 HK, 411 DK
Gaps: 0




```

# Formal
# Author: [Name]
# Title: [Title]
# Abstract: [Abstract]
# Keywords: [Keywords]
# Cross-References: [Cross-References]
# Acknowledgments: [Acknowledgments]
# Funding: [Funding]
# Distribution: [Distribution]
# Copyright: [Copyright]
# License: [License]
# Revision: [Revision]
# Date: [Date]
# Version: [Version]
# Status: [Status]
# Priority: [Priority]
# Classification: [Classification]
# Security: [Security]
# Access: [Access]
# Comments: [Comments]
# Notes: [Notes]
# References: [References]
# Bibliography: [Bibliography]
# Appendix: [Appendix]
# Glossary: [Glossary]
# Index: [Index]
# Table of Contents: [Table of Contents]
# Table: [Table]
# Figure: [Figure]
# Equation: [Equation]
# Formula: [Formula]
# Diagram: [Diagram]
# Map: [Map]
# Photograph: [Photograph]
# Video: [Video]
# Audio: [Audio]
# Software: [Software]
# Hardware: [Hardware]
# Data: [Data]
# Results: [Results]
# Discussion: [Discussion]
# Conclusion: [Conclusion]
# Summary: [Summary]
# Abstract: [Abstract]
# Keywords: [Keywords]
# Cross-References: [Cross-References]
# Acknowledgments: [Acknowledgments]
# Funding: [Funding]
# Distribution: [Distribution]
# Copyright: [Copyright]
# License: [License]
# Revision: [Revision]
# Date: [Date]
# Version: [Version]
# Status: [Status]
# Priority: [Priority]
# Classification: [Classification]
# Security: [Security]
# Access: [Access]
# Comments: [Comments]
# Notes: [Notes]
# References: [References]
# Bibliography: [Bibliography]
# Appendix: [Appendix]
# Glossary: [Glossary]
# Index: [Index]
# Table of Contents: [Table of Contents]
# Table: [Table]
# Figure: [Figure]
# Equation: [Equation]
# Formula: [Formula]
# Diagram: [Diagram]
# Map: [Map]
# Photograph: [Photograph]
# Video: [Video]
# Audio: [Audio]
# Software: [Software]
# Hardware: [Hardware]
# Data: [Data]
# Results: [Results]
# Discussion: [Discussion]
# Conclusion: [Conclusion]
# Summary: [Summary]

```

```

# Formal
# Author: [Name]
# Title: [Title]
# Abstract: [Abstract]
# Keywords: [Keywords]
# Cross-References: [Cross-References]
# Acknowledgments: [Acknowledgments]
# Funding: [Funding]
# Distribution: [Distribution]
# Copyright: [Copyright]
# License: [License]
# Revision: [Revision]
# Date: [Date]
# Version: [Version]
# Status: [Status]
# Priority: [Priority]
# Classification: [Classification]
# Security: [Security]
# Access: [Access]
# Comments: [Comments]
# Notes: [Notes]
# References: [References]
# Bibliography: [Bibliography]
# Appendix: [Appendix]
# Glossary: [Glossary]
# Index: [Index]
# Table of Contents: [Table of Contents]
# Table: [Table]
# Figure: [Figure]
# Equation: [Equation]
# Formula: [Formula]
# Diagram: [Diagram]
# Map: [Map]
# Photograph: [Photograph]
# Video: [Video]
# Audio: [Audio]
# Software: [Software]
# Hardware: [Hardware]
# Data: [Data]
# Results: [Results]
# Discussion: [Discussion]
# Conclusion: [Conclusion]
# Summary: [Summary]
# Abstract: [Abstract]
# Keywords: [Keywords]
# Cross-References: [Cross-References]
# Acknowledgments: [Acknowledgments]
# Funding: [Funding]
# Distribution: [Distribution]
# Copyright: [Copyright]
# License: [License]
# Revision: [Revision]
# Date: [Date]
# Version: [Version]
# Status: [Status]
# Priority: [Priority]
# Classification: [Classification]
# Security: [Security]
# Access: [Access]
# Comments: [Comments]
# Notes: [Notes]
# References: [References]
# Bibliography: [Bibliography]
# Appendix: [Appendix]
# Glossary: [Glossary]
# Index: [Index]
# Table of Contents: [Table of Contents]
# Table: [Table]
# Figure: [Figure]
# Equation: [Equation]
# Formula: [Formula]
# Diagram: [Diagram]
# Map: [Map]
# Photograph: [Photograph]
# Video: [Video]
# Audio: [Audio]
# Software: [Software]
# Hardware: [Hardware]
# Data: [Data]
# Results: [Results]
# Discussion: [Discussion]
# Conclusion: [Conclusion]
# Summary: [Summary]

```


Dr. David A. A. Zelen, Fellow, Macromolecular Research Unit,
Department of Chemistry, University of Edinburgh, U.K.
Dr. J. H. Duerksen, Department of Chemistry, University of Oxford, Oxford, U.K.

[illegible]

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains. The concentration of the *Agrobacterium* suspension was 10⁶ cells/ml (○), 10⁷ cells/ml (□), 10⁸ cells/ml (△), and 10⁹ cells/ml (◇). The data were the mean of three independent experiments. Error bars represent standard deviation.

[illegible][illegible][illegible]

There is no doubt that the book is a valuable addition to the literature on the history of the book. It is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers. The book is a valuable addition to the literature on the history of the book. It is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers.

Figure 1: A schematic diagram of the proposed system. The input image I is processed by a feature extractor F to produce a feature map $F(I)$. This feature map is then processed by a series of modules: a residual block R , a global average pooling layer GAP , and a fully connected layer FC . The output of the FC layer is a vector v , which is then processed by a softmax layer S to produce the final output O .

| | | | |
|------|-----------|------------|----------|
| 1 | HEM-GLDIN | BETA CHAIN | 1,046-01 |
| 2 | HEM-GLDIN | BETA CHAIN | 1,047-01 |
| 3 | HEM-GLDIN | BETA CHAIN | 1,048-01 |
| 4 | HEM-SHLEP | BETA CHAIN | 1,049-01 |
| 5 | HEM-GLDIN | BETA CHAIN | 1,050-01 |
| 6 | HEM-GLDIN | BETA CHAIN | 1,051-01 |
| 7 | HEM-GLDIN | BETA CHAIN | 1,052-01 |
| 8 | HEM-GLDIN | BETA CHAIN | 1,053-01 |
| 9 | HEM-GLDIN | BETA CHAIN | 1,054-01 |
| 10 | HEM-GLDIN | BETA CHAIN | 1,055-01 |
| 11 | HEM-GLDIN | BETA CHAIN | 1,056-01 |
| 12 | HEM-GLDIN | BETA CHAIN | 1,057-01 |
| 13 | HEM-GLDIN | BETA CHAIN | 1,058-01 |
| 14 | HEM-GLDIN | BETA CHAIN | 1,059-01 |
| 15 | HEM-GLDIN | BETA CHAIN | 1,060-01 |
| 16 | HEM-GLDIN | BETA CHAIN | 1,061-01 |
| 17 | HEM-GLDIN | BETA CHAIN | 1,062-01 |
| 18 | HEM-GLDIN | BETA CHAIN | 1,063-01 |
| 19 | HEM-GLDIN | BETA CHAIN | 1,064-01 |
| 20 | HEM-GLDIN | BETA CHAIN | 1,065-01 |
| 21 | HEM-GLDIN | BETA CHAIN | 1,066-01 |
| 22 | HEM-GLDIN | BETA CHAIN | 1,067-01 |
| 23 | HEM-GLDIN | BETA CHAIN | 1,068-01 |
| 24 | HEM-GLDIN | BETA CHAIN | 1,069-01 |
| 25 | HEM-GLDIN | BETA CHAIN | 1,070-01 |
| 26 | HEM-GLDIN | BETA CHAIN | 1,071-01 |
| 27 | HEM-GLDIN | BETA CHAIN | 1,072-01 |
| 28 | HEM-GLDIN | BETA CHAIN | 1,073-01 |
| 29 | HEM-GLDIN | BETA CHAIN | 1,074-01 |
| 30 | HEM-GLDIN | BETA CHAIN | 1,075-01 |
| 31 | HEM-GLDIN | BETA CHAIN | 1,076-01 |
| 32 | HEM-GLDIN | BETA CHAIN | 1,077-01 |
| 33 | HEM-GLDIN | BETA CHAIN | 1,078-01 |
| 34 | HEM-GLDIN | BETA CHAIN | 1,079-01 |
| 35 | HEM-GLDIN | BETA CHAIN | 1,080-01 |
| 36 | HEM-GLDIN | BETA CHAIN | 1,081-01 |
| 37 | HEM-GLDIN | BETA CHAIN | 1,082-01 |
| 38 | HEM-GLDIN | BETA CHAIN | 1,083-01 |
| 39 | HEM-GLDIN | BETA CHAIN | 1,084-01 |
| 40 | HEM-GLDIN | BETA CHAIN | 1,085-01 |
| 41 | HEM-GLDIN | BETA CHAIN | 1,086-01 |
| 42 | HEM-GLDIN | BETA CHAIN | 1,087-01 |
| 43 | HEM-GLDIN | BETA CHAIN | 1,088-01 |
| 44 | HEM-GLDIN | BETA CHAIN | 1,089-01 |
| 45 | HEM-GLDIN | BETA CHAIN | 1,090-01 |
| 46 | HEM-GLDIN | BETA CHAIN | 1,091-01 |
| 47 | HEM-GLDIN | BETA CHAIN | 1,092-01 |
| 48 | HEM-GLDIN | BETA CHAIN | 1,093-01 |
| 49 | HEM-GLDIN | BETA CHAIN | 1,094-01 |
| 50 | HEM-GLDIN | BETA CHAIN | 1,095-01 |
| 51 | HEM-GLDIN | BETA CHAIN | 1,096-01 |
| 52 | HEM-GLDIN | BETA CHAIN | 1,097-01 |
| 53 | HEM-GLDIN | BETA CHAIN | 1,098-01 |
| 54 | HEM-GLDIN | BETA CHAIN | 1,099-01 |
| 55 | HEM-GLDIN | BETA CHAIN | 1,100-01 |
| 56 | HEM-GLDIN | BETA CHAIN | 1,101-01 |
| 57 | HEM-GLDIN | BETA CHAIN | 1,102-01 |
| 58 | HEM-GLDIN | BETA CHAIN | 1,103-01 |
| 59 | HEM-GLDIN | BETA CHAIN | 1,104-01 |
| 60 | HEM-GLDIN | BETA CHAIN | 1,105-01 |
| 61 | HEM-GLDIN | BETA CHAIN | 1,106-01 |
| 62 | HEM-GLDIN | BETA CHAIN | 1,107-01 |
| 63 | HEM-GLDIN | BETA CHAIN | 1,108-01 |
| 64 | HEM-GLDIN | BETA CHAIN | 1,109-01 |
| 65 | HEM-GLDIN | BETA CHAIN | 1,110-01 |
| 66 | HEM-GLDIN | BETA CHAIN | 1,111-01 |
| 67 | HEM-GLDIN | BETA CHAIN | 1,112-01 |
| 68 | HEM-GLDIN | BETA CHAIN | 1,113-01 |
| 69 | HEM-GLDIN | BETA CHAIN | 1,114-01 |
| 70 | HEM-GLDIN | BETA CHAIN | 1,115-01 |
| 71 | HEM-GLDIN | BETA CHAIN | 1,116-01 |
| 72 | HEM-GLDIN | BETA CHAIN | 1,117-01 |
| 73 | HEM-GLDIN | BETA CHAIN | 1,118-01 |
| 74 | HEM-GLDIN | BETA CHAIN | 1,119-01 |
| 75 | HEM-GLDIN | BETA CHAIN | 1,120-01 |
| 76 | HEM-GLDIN | BETA CHAIN | 1,121-01 |
| 77 | HEM-GLDIN | BETA CHAIN | 1,122-01 |
| 78 | HEM-GLDIN | BETA CHAIN | 1,123-01 |
| 79 | HEM-GLDIN | BETA CHAIN | 1,124-01 |
| 80 | HEM-GLDIN | BETA CHAIN | 1,125-01 |
| 81 | HEM-GLDIN | BETA CHAIN | 1,126-01 |
| 82 | HEM-GLDIN | BETA CHAIN | 1,127-01 |
| 83 | HEM-GLDIN | BETA CHAIN | 1,128-01 |
| 84 | HEM-GLDIN | BETA CHAIN | 1,129-01 |
| 85 | HEM-GLDIN | BETA CHAIN | 1,130-01 |
| 86 | HEM-GLDIN | BETA CHAIN | 1,131-01 |
| 87 | HEM-GLDIN | BETA CHAIN | 1,132-01 |
| 88 | HEM-GLDIN | BETA CHAIN | 1,133-01 |
| 89 | HEM-GLDIN | BETA CHAIN | 1,134-01 |
| 90 | HEM-GLDIN | BETA CHAIN | 1,135-01 |
| 91 | HEM-GLDIN | BETA CHAIN | 1,136-01 |
| 92 | HEM-GLDIN | BETA CHAIN | 1,137-01 |
| 93 | HEM-GLDIN | BETA CHAIN | 1,138-01 |
| 94</ | | | |

| | | | | | | | | |
|----|----|-----|---|----------|------------|------|------|-----|
| 27 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 28 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 29 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 30 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 31 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 32 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 33 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 34 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 35 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 36 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 37 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 38 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 39 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 40 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 41 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 42 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 43 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 44 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |
| 45 | 50 | 100 | 1 | HBB-NANA | HEM-GLORIN | HEIA | THAN | 100 |

ALLEN, C.

[illegible]

only half.
Net Local Simultaneous
Ratings S; Conservative C; Moderate M; Liberal L;
OL P; RPTQ 89

[illegible]

CC CURRENT APPLICATION DATA:
CC APPLICANT: NIX N VAN DERBYE P O
CC STREET: 1100 N FISH GLEBE RD
CC CITY: ARLINGTON
CC STATE: VIRGINIA
CC COUNTRY: U.S.A.
CC ZIP: 22201-4714
CC COMPUTER RESEARCH FIRM:
CC METHOD TYPE: FISHY DISK
CC PRIORITY: 199 00 0000000000
CC PENDING SYSTEM: 000000000000
CC SOFTWARE: 000000000000000000
CC CURRENT APPLICATION DATA:
CC APPLICANT: NIX N VAN DERBYE P O
CC STREET: 1100 N FISH GLEBE RD
CC CITY: ARLINGTON
CC STATE: VIRGINIA
CC COUNTRY: U.S.A.
CC ZIP: 22201-4714
CC COMPUTER RESEARCH FIRM:
CC METHOD TYPE: FISHY DISK
CC PRIORITY: 199 00 0000000000
CC PENDING SYSTEM: 000000000000
CC SOFTWARE: 000000000000000000

CC SOFTWARE: Patent Release #1.0. Version #1.0
CC CURRENT APPLICATION DATA:
CC APPLICANT: NIX N VAN DERBYE P O
CC STREET: 1100 N FISH GLEBE RD
CC CITY: ARLINGTON
CC STATE: VIRGINIA
CC COUNTRY: U.S.A.
CC ZIP: 22201-4714
CC COMPUTER RESEARCH FIRM:
CC METHOD TYPE: FISHY DISK
CC PRIORITY: 199 00 0000000000
CC PENDING SYSTEM: 000000000000
CC SOFTWARE: 000000000000000000
CC CURRENT APPLICATION DATA:
CC APPLICANT: NIX N VAN DERBYE P O
CC STREET: 1100 N FISH GLEBE RD
CC CITY: ARLINGTON
CC STATE: VIRGINIA
CC COUNTRY: U.S.A.
CC ZIP: 22201-4714
CC COMPUTER RESEARCH FIRM:
CC METHOD TYPE: FISHY DISK
CC PRIORITY: 199 00 0000000000
CC PENDING SYSTEM: 000000000000
CC SOFTWARE: 000000000000000000

CC 43 EPHEDRINE
CC 2 EPHEDRINE
CC 141 AA
CC 141 AA

CC 43 EPHEDRINE
CC 2 EPHEDRINE
CC 141 AA
CC 141 AA

CC 43 EPHEDRINE
CC 2 EPHEDRINE
CC 141 AA
CC 141 AA

CC 43 EPHEDRINE
CC 2 EPHEDRINE
CC 141 AA
CC 141 AA

CC 43 EPHEDRINE
CC 2 EPHEDRINE
CC 141 AA
CC 141 AA



FILED
FBI - MEMPHIS

SEARCHED INDEXED SERIALIZED FILED
NOV 15 1999 FBI - MEMPHIS





100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

| Source | Ref | Category | Subcategory | Product No. |
|--------|-----|----------|-------------|-------------|
| 1 | 1 | 1 | 1 | 1 |
| 2 | 2 | 2 | 2 | 2 |
| 3 | 3 | 3 | 3 | 3 |
| 4 | 4 | 4 | 4 | 4 |
| 5 | 5 | 5 | 5 | 5 |
| 6 | 6 | 6 | 6 | 6 |
| 7 | 7 | 7 | 7 | 7 |
| 8 | 8 | 8 | 8 | 8 |
| 9 | 9 | 9 | 9 | 9 |
| 10 | 10 | 10 | 10 | 10 |
| 11 | 11 | 11 | 11 | 11 |
| 12 | 12 | 12 | 12 | 12 |
| 13 | 13 | 13 | 13 | 13 |
| 14 | 14 | 14 | 14 | 14 |
| 15 | 15 | 15 | 15 | 15 |
| 16 | 16 | 16 | 16 | 16 |
| 17 | 17 | 17 | 17 | 17 |
| 18 | 18 | 18 | 18 | 18 |
| 19 | 19 | 19 | 19 | 19 |
| 20 | 20 | 20 | 20 | 20 |
| 21 | 21 | 21 | 21 | 21 |
| 22 | 22 | 22 | 22 | 22 |
| 23 | 23 | 23 | 23 | 23 |
| 24 | 24 | 24 | 24 | 24 |
| 25 | 25 | 25 | 25 | 25 |
| 26 | 26 | 26 | 26 | 26 |
| 27 | 27 | 27 | 27 | 27 |
| 28 | 28 | 28 | 28 | 28 |
| 29 | 29 | 29 | 29 | 29 |
| 30 | 30 | 30 | 30 | 30 |
| 31 | 31 | 31 | 31 | 31 |
| 32 | 32 | 32 | 32 | 32 |
| 33 | 33 | 33 | 33 | 33 |
| 34 | 34 | 34 | 34 | 34 |
| 35 | 35 | 35 | 35 | 35 |
| 36 | 36 | 36 | 36 | 36 |
| 37 | 37 | 37 | 37 | 37 |
| 38 | 38 | 38 | 38 | 38 |
| 39 | 39 | 39 | 39 | 39 |
| 40 | 40 | 40 | 40 | 40 |
| 41 | 41 | 41 | 41 | 41 |
| 42 | 42 | 42 | 42 | 42 |
| 43 | 43 | 43 | 43 | 43 |
| 44 | 44 | 44 | 44 | 44 |
| 45 | 45 | 45 | 45 | 45 |
| 46 | 46 | 46 | 46 | 46 |
| 47 | 47 | 47 | 47 | 47 |
| 48 | 48 | 48 | 48 | 48 |
| 49 | 49 | 49 | 49 | 49 |
| 50 | 50 | 50 | 50 | 50 |
| 51 | 51 | 51 | 51 | 51 |
| 52 | 52 | 52 | 52 | 52 |
| 53 | 53 | 53 | 53 | 53 |
| 54 | 54 | 54 | 54 | 54 |
| 55 | 55 | 55 | 55 | 55 |
| 56 | 56 | 56 | 56 | 56 |
| 57 | 57 | 57 | 57 | 57 |
| 58 | 58 | 58 | 58 | 58 |
| 59 | 59 | 59 | 59 | 59 |
| 60 | 60 | 60 | 60 | 60 |
| 61 | 61 | 61 | 61 | 61 |
| 62 | 62 | 62 | 62 | 62 |
| 63 | 63 | 63 | 63 | 63 |
| 64 | 64 | 64 | 64 | 64 |
| 65 | 65 | 65 | 65 | 65 |
| 66 | 66 | 66 | 66 | 66 |
| 67 | 67 | 67 | 67 | 67 |
| 68 | 68 | 68 | 68 | 68 |
| 69 | 69 | 69 | 69 | 69 |
| 70 | 70 | 70 | 70 | 70 |
| 71 | 71 | 71 | 71 | 71 |
| 72 | 72 | 72 | 72 | 72 |
| 73 | 73 | 73 | 73 | 73 |
| 74 | 74 | 74 | 74 | 74 |
| 75 | 75 | 75 | 75 | 75 |
| 76 | 76 | 76 | 76 | 76 |
| 77 | 77 | 77 | 77 | 77 |
| 78 | 78 | 78 | 78 | 78 |
| 79 | 79 | 79 | 79 | 79 |
| 80 | 80 | 80 | 80 | 80 |
| 81 | 81 | 81 | 81 | 81 |
| 82 | 82 | 82 | 82 | 82 |
| 83 | 83 | 83 | 83 | 83 |
| 84 | 84 | 84 | 84 | 84 |
| 85 | 85 | 85 | 85 | 85 |
| 86 | 86 | 86 | 86 | 86 |
| 87 | 87 | 87 | 87 | 87 |
| 88 | 88 | 88 | 88 | 88 |
| 89 | 89 | 89 | 89 | 89 |
| 90 | 90 | 90 | 90 | 90 |
| 91 | 91 | 91 | 91 | 91 |
| 92 | 92 | 92 | 92 | 92 |
| 93 | 93 | 93 | 93 | 93 |
| 94 | 94 | 94 | 94 | 94 |
| 95 | 95 | 95 | 95 | 95 |
| 96 | 96 | 96 | 96 | 96 |
| 97 | 97 | 97 | 97 | 97 |
| 98 | 98 | 98 | 98 | 98 |
| 99 | 99 | 99 | 99 | 99 |
| 100 | 100 | 100 | 100 | 100 |


| Result | Ref | Category | Subcategory | Product No. |
|--------|-----|----------|-------------|-------------|
| 1 | 1 | 1 | 1 | 1 |
| 2 | 2 | 2 | 2 | 2 |
| 3 | 3 | 3 | 3 | 3 |
| 4 | 4 | 4 | 4 | 4 |
| 5 | 5 | 5 | 5 | 5 |
| 6 | 6 | 6 | 6 | 6 |
| 7 | 7 | 7 | 7 | 7 |
| 8 | 8 | 8 | 8 | 8 |
| 9 | 9 | 9 | 9 | 9 |
| 10 | 10 | 10 | 10 | 10 |
| 11 | 11 | 11 | 11 | 11 |
| 12 | 12 | 12 | 12 | 12 |
| 13 | 13 | 13 | 13 | 13 |
| 14 | 14 | 14 | 14 | 14 |
| 15 | 15 | 15 | 15 | 15 |
| 16 | 16 | 16 | 16 | 16 |
| 17 | 17 | 17 | 17 | 17 |
| 18 | 18 | 18 | 18 | 18 |
| 19 | 19 | 19 | 19 | 19 |
| 20 | 20 | 20 | 20 | 20 |
| 21 | 21 | 21 | 21 | 21 |
| 22 | 22 | 22 | 22 | 22 |
| 23 | 23 | 23 | 23 | 23 |
| 24 | 24 | 24 | 24 | 24 |
| 25 | 25 | 25 | 25 | 25 |
| 26 | 26 | 26 | 26 | 26 |
| 27 | 27 | 27 | 27 | 27 |
| 28 | 28 | 28 | 28 | 28 |
| 29 | 29 | 29 | 29 | 29 |
| 30 | 30 | 30 | 30 | 30 |
| 31 | 31 | 31 | 31 | 31 |
| 32 | 32 | 32 | 32 | 32 |
| 33 | 33 | 33 | 33 | 33 |
| 34 | 34 | 34 | 34 | 34 |
| 35 | 35 | 35 | 35 | 35 |
| 36 | 36 | 36 | 36 | 36 |
| 37 | 37 | 37 | 37 | 37 |
| 38 | 38 | 38 | 38 | 38 |
| 39 | 39 | 39 | 39 | 39 |
| 40 | 40 | 40 | 40 | 40 |
| 41 | 41 | 41 | 41 | 41 |
| 42 | 42 | 42 | 42 | 42 |
| 43 | 43 | 43 | 43 | 43 |
| 44 | 44 | 44 | 44 | 44 |
| 45 | 45 | 45 | 45 | 45 |
| 46 | 46 | 46 | 46 | 46 |
| 47 | 47 | 47 | 47 | 47 |
| 48 | 48 | 48 | 48 | 48 |
| 49 | 49 | 49 | 49 | 49 |
| 50 | 50 | 50 | 50 | 50 |
| 51 | 51 | 51 | 51 | 51 |
| 52 | 52 | 52 | 52 | 52 |
| 53 | 53 | 53 | 53 | 53 |
| 54 | 54 | 54 | 54 | 54 |
| 55 | 55 | 55 | 55 | 55 |
| 56 | 56 | 56 | 56 | 56 |
| 57 | 57 | 57 | 57 | 57 |
| 58 | 58 | 58 | 58 | 58 |
| 59 | 59 | 59 | 59 | 59 |
| 60 | 60 | 60 | 60 | 60 |
| 61 | 61 | 61 | 61 | 61 |
| 62 | 62 | 62 | 62 | 62 |
| 63 | 63 | 63 | 63 | 63 |
| 64 | 64 | 64 | 64 | 64 |
| 65 | 65 | 65 | 65 | 65 |
| 66 | 66 | 66 | 66 | 66 |
| 67 | 67 | 67 | 67 | 67 |
| 68 | 68 | 68 | 68 | 68 |
| 69 | 69 | 69 | 69 | 69 |
| 70 | 70 | 70 | 70 | 70 |
| 71 | 71 | 71 | 71 | 71 |
| 72 | 72 | 72 | 72 | 72 |
| 73 | 73 | 73 | 73 | 73 |
| 74 | 74 | 74 | 74 | 74 |
| 75 | 75 | 75 | 75 | 75 |
| 76 | 76 | 76 | 76 | 76 |
| 77 | 77 | 77 | 77 | 77 |
| 78 | 78 | 78 | 78 | 78 |
| 79 | 79 | 79 | 79 | 79 |
| 80 | 80 | 80 | 80 | 80 |
| 81 | 81 | 81 | 81 | 81 |
| 82 | 82 | 82 | 82 | 82 |
| 83 | 83 | 83 | 83 | 83 |
| 84 | 84 | 84 | 84 | 84 |
| 85 | 85 | 85 | 85 | 85 |
| 86 | 86 | 86 | 86 | 86 |
| 87 | 87 | 87 | 87 | 87 |
| 88 | 88 | 88 | 88 | 88 |
| 89 | 89 | 89 | 89 | 89 |
| 90 | 90 | 90 | 90 | 90 |
| 91 | 91 | 91 | 91 | 91 |
| 92 | 92 | 92 | 92 | 92 |
| 93 | 93 | 93 | 93 | 93 |
| 94 | 94 | 94 | 94 | 94 |
| 95 | 95 | 95 | 95 | 95 |
| 96 | 96 | 96 | 96 | 96 |
| 97 | 97 | 97 | 97 | 97 |
| 98 | 98 | 98 | 98 | 98 |
| 99 | 99 | 99 | 99 | 99 |
| 100 | 100 | 100 | 100 | 100 |

11 CATARRH: HEMISPHERAL: HEMISPHERAL
 12 111
 13 SEQUENCE FROM N.A.
 14 111
 15 111
 16 111
 17 111
 18 111
 19 111
 20 111
 21 111
 22 111
 23 111
 24 111
 25 111
 26 111
 27 111
 28 111
 29 111
 30 111
 31 111
 32 111
 33 111
 34 111
 35 111
 36 111
 37 111
 38 111
 39 111
 40 111
 41 111
 42 111
 43 111
 44 111
 45 111
 46 111
 47 111
 48 111
 49 111
 50 111
 51 111
 52 111
 53 111
 54 111
 55 111
 56 111
 57 111
 58 111
 59 111
 60 111
 61 111
 62 111
 63 111
 64 111
 65 111
 66 111
 67 111
 68 111
 69 111
 70 111
 71 111
 72 111
 73 111
 74 111
 75 111
 76 111
 77 111
 78 111
 79 111
 80 111
 81 111
 82 111
 83 111
 84 111
 85 111
 86 111
 87 111
 88 111
 89 111
 90 111
 91 111
 92 111
 93 111
 94 111
 95 111
 96 111
 97 111
 98 111
 99 111
 100 111

11 CATARRH: HEMISPHERAL: HEMISPHERAL
 12 111
 13 SEQUENCE FROM N.A.
 14 111
 15 111
 16 111
 17 111
 18 111
 19 111
 20 111
 21 111
 22 111
 23 111
 24 111
 25 111
 26 111
 27 111
 28 111
 29 111
 30 111
 31 111
 32 111
 33 111
 34 111
 35 111
 36 111
 37 111
 38 111
 39 111
 40 111
 41 111
 42 111
 43 111
 44 111
 45 111
 46 111
 47 111
 48 111
 49 111
 50 111
 51 111
 52 111
 53 111
 54 111
 55 111
 56 111
 57 111
 58 111
 59 111
 60 111
 61 111
 62 111
 63 111
 64 111
 65 111
 66 111
 67 111
 68 111
 69 111
 70 111
 71 111
 72 111
 73 111
 74 111
 75 111
 76 111
 77 111
 78 111
 79 111
 80 111
 81 111
 82 111
 83 111
 84 111
 85 111
 86 111
 87 111
 88 111
 89 111
 90 111
 91 111
 92 111
 93 111
 94 111
 95 111
 96 111
 97 111
 98 111
 99 111
 100 111



ALL INFORMATION CONTAINED
HEREIN IS UNCLASSIFIED
DATE 11-15-99 BY 60322
UCBAW







[illegible]

Figure 1 illustrates the steps of the proposed algorithm for finding the minimum spanning tree of a graph. The graphs are labeled (a) through (g). (a) shows a graph with 7 vertices and 10 edges, with a highlighted path. (b) shows the graph with one edge removed. (c) shows the graph with two edges removed. (d) shows the graph with three edges removed. (e) shows the graph with four edges removed. (f) shows the graph with five edges removed. (g) shows the final minimum spanning tree with 6 vertices and 5 edges.

6

the fact that the *in vitro* and *in vivo* results are in good agreement. The *in vivo* results are in good agreement with the *in vitro* results, which are in good agreement with the *in vivo* results.

On 22 November 2000, the *Journal of the American Medical Association* published a study by the National Cancer Institute (NCI) that showed that the use of tamoxifen in the treatment of breast cancer was associated with a 25% increase in the risk of developing a blood clot (1). The study was a retrospective analysis of data from the NCI's Breast International Group (BIG) 1-98 trial, which was a randomized, controlled trial of tamoxifen versus placebo in the treatment of breast cancer. The study found that the risk of developing a blood clot was significantly higher in the tamoxifen group than in the placebo group. The study also found that the risk of developing a blood clot was higher in patients who had a history of blood clots, who were taking other medications that increased the risk of blood clots, and who had a family history of blood clots. The study was widely cited in the media, and it led to a significant increase in the use of tamoxifen in the treatment of breast cancer. However, the study also led to a significant increase in the use of blood thinners in the treatment of breast cancer, which is a controversial issue. The study was also criticized for its methodology, which was retrospective and did not control for many factors that could have influenced the results. The study was also criticized for its lack of transparency, as the NCI did not release the full text of the study until several months after it was published. The study was also criticized for its lack of statistical significance, as the increase in the risk of developing a blood clot was not statistically significant in the tamoxifen group. The study was also criticized for its lack of clinical significance, as the increase in the risk of developing a blood clot was not clinically significant. The study was also criticized for its lack of ethical considerations, as the NCI did not obtain informed consent from the patients who participated in the study. The study was also criticized for its lack of ethical considerations, as the NCI did not obtain informed consent from the patients who participated in the study.

[illegible]

HSP-1 600-2000 Hz. Band
 HEPER CRYSTAL TRANSDUCER RESONANT AT 10.0 MHz. DRIVER: 200 W
 1000 Hz. NUTTER 1000 Hz. 4000 Hz. 1000 Hz. 4000 Hz. 1000 Hz.
 SOURCE 1000 Hz. 4000 Hz. 1000 Hz. 4000 Hz. 1000 Hz. 4000 Hz.

 W E E K L Y
 (TW)

 W E E K L Y
 (TW)

 W E E K L Y
 (TW)

 W E E K L Y
 (TW)

 W E E K L Y
 (TW)

 W E E K L Y
 (TW)

 W E E K L Y
 (TW)

 W E E K L Y
 (TW)

 W E E K L Y
 (TW)

 W E E K L Y
 (TW)

 W E E K L Y
 (TW)

 W E E K L Y
 (TW)

 W E E K L Y
 (TW)

 W E E K L Y
 (TW)

ALIGNMENTS

 W E E K L Y
 (TW)



